Before you leave...
Take 20% off your first order
20% off
Enter the code below at checkout to get 20% off your first order
Discover summer reading lists for all ages & interests!
Find Your Next Read
This book is an engaging and insightful exploration of cause-and-effect relationships in clinical research. It begins with the foundational principles of causal inference, traces the historical evolution of randomized controlled trials, and provides a clear, comprehensive explanation of the essential elements of ICH E9(R1). The central themes of ICH E9(R1) - defining the clinical question of primary importance and establishing the estimand to answer that question - are seamlessly integrated throughout the narrative.
A standout feature is the introduction of the Tripartite Estimand Approach, a groundbreaking framework derived from patient and physician perspectives. This approach addresses the critical questions and answers needed for informed prescribing decisions. The book also outlines a stepwise, logical process for implementing the estimand framework, offering practical guidance for clinicians, statisticians, and other professionals involved in clinical drug development. By simplifying complex concepts, this book aims to make the estimand framework more accessible and actionable across disciplines. While aligned with the principles of ICH E9(R1), the book goes beyond the established guidelines, presenting bold new ideas and perspectives that enhance the understanding of estimands.
Key Features:
Written in a conversational style with minimal mathematical notation, Does This Treatment Cause That Outcome?: The Science of Estimating a Treatment Effect and Why It Matters is designed to be accessible to clinicians and non-statistical professionals, making it an invaluable resource for anyone involved in clinical drug development. Whether you are a seasoned statistician or new to the field, this book provides the tools and insights needed to navigate the estimand framework with confidence and clarity.
Dr. Stephen Ruberg received a BA in mathematics from Thomas More College, an MS in Statistics from Miami of Ohio, and a PhD in Biostatistics from the University of Cincinnati.
Dr. Ruberg was in the pharma industry for 38 years and worked across drug development and commercialization - from R&D to Business Analytics. Throughout his career, Steve had senior leadership roles, including VP of Statistics and Data Management at several companies. While at Lilly, he formed the Advanced Analytics Hub and was its Scientific Leader. He was ultimately named a Distinguished Research Fellow in Lilly R&D. Dr. Ruberg served in many leadership roles in the pharmaceutical industry and statistical profession. He co-authored ICH-E9 Statistical Principles for Clinical Trials, and most notably, Steve served on a select Advisory Committee to the Secretary of Health and Human Services during the Bush administration for advancing the use of electronic medical records.
After retiring from Lilly in 2017, Dr. Ruberg has founded his own consulting firm, Analytix Thinking, LLC, which focuses on consulting and teaching pharma companies big and small, as well as lecturing and publishing on important statistical topics. Dr. Ruberg's current research interests include estimands, subgroup identification, Bayesian methods for clinical drug development, and digital medicine. He has been a Fellow of the American Statistical Association since 1994, was given the Career Achievement Award by Quantitative Scientists in the Pharmaceutical Industry and was elected a Fellow of International Statistics Institute.
Thanks for subscribing!
This email has been registered!
Take 20% off your first order
Enter the code below at checkout to get 20% off your first order